The chart of Kamada Ltd (KMDA) shows a double top with $6.13 target or 3.00% above today’s $5.95 share price. The 6 months chart pattern indicates low risk for the $216.69 million company. It was reported on Jan, 11 by Finviz.com. If the $6.13 price target is reached, the company will be worth $6.50M more. Double tops are rare but powerful chart patterns. The stock last traded at $5.95 per share. It is up 60.38% since June 7, 2016 and is uptrending. It has outperformed by 52.95% the S&P500.
Analysts await Kamada Ltd (NASDAQ:KMDA) to report earnings on February, 7. They expect $-0.04 EPS, down 233.33% or $0.07 from last year’s $0.03 per share. After $-0.03 actual EPS reported by Kamada Ltd for the previous quarter, Wall Street now forecasts 33.33% negative EPS growth.
According to Zacks Investment Research, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.”
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.